Mechanisms in Myelodysplastic Syndromes
This learning activity has been designated for 1.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
After successfully completing this activity, you should be able to:
- Integrate patients’ laboratory results into defined and emerging classification algorithms of Myelodysplastic Syndromes (MDS)
- Employ prognostic scoring systems to strategically design treatment plans
- Review the recommended treatment strategies for higher-risk MDS and discuss how they could be affected by new clinical trial findings
- Describe at least 3 emerging agents or combinations for higher-risk MDS and evaluate clinical trial results for each
This online, animated CME resource is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat patients with MDS.
Release Date: December 31, 2010
Expiration date: December 31, 2011
(*Please check this box to proceed - required)
Start the Module